Spa Executive

JULY 17, 2024

Catherine Warren is Vice President of Strategic Partnerships at Arch Amenities Group, a provider of comprehensive amenity management and consulting services for hotels, residential complexes, and commercial real estate. Moreover, I’m excited about the prospect of scaling our impact through education and training initiatives.

Technology 98

Technology Hospital Sustainability Innovations 98

The Dermatology Digest

SEPTEMBER 30, 2024

market, is an important milestone on our pathway to consistently broadening our biopharma portfolio in the U.S. Otulfi demonstrated comparable efficacy, safety, pharmacokinetics and immunogenicity to Stelara in patients with moderate to severe psoriasis vulgaris. and worldwide.

Portfolios 36

Portfolios Partnerships Marketing Safety 36

The Dermatology Digest

SEPTEMBER 9, 2024

“China has always been a strategic market for Sisram, and the approval of Daxxify serves as a key milestone for bringing Sisram’s high-end injectables portfolio to Mainland China,” says Mr. Liu Yi, Sisram Chairman and Executive Director, in a news release.

Portfolios 36

Portfolios Dermatology Injections Marketing 36

AAAMS

APRIL 18, 2024

This comprehensive knowledge ensures not only the safety and satisfaction of patients but also elevates the provider’s reputation, setting the groundwork for a thriving practice. You’ll also learn to assess a client’s face, plan treatment strategies, and ensure safety to avoid complications. Networking is your ally.

Injections 40

Injections Training Legal Safety 40

Aesthetics Advisor

SEPTEMBER 15, 2023

The pharmacology, toxicity, and safety data for NO use in humans has been well-established for decades. Glenmark Pharmaceuticals has signed a partnership with Canadian company SaNOtize Research & Development Corp., You can purchase it online on Amazon.com.

Hospital 69

Hospital Clinic Marketing Medical 69

The Dermatology Digest

MARCH 27, 2025

This partnership builds on the positive Phase 2 clinical data of ESK-001, our next-generation oral TYK2 inhibitor, supporting our objectives to unlock its full therapeutic potential and ensure ESK-001 is widely accessible to people with immune-mediated disorders around the world.

Pharmaceutical 36

Pharmaceutical Portfolios Clinic Safety 36